Asia-focused PE firm PAG has purchased a majority stake in Hisun BioRay, the biotech division of Chinese state-owned generic company Zhejiang Hisun Pharmaceutical, for $540m, boosting its presence in a nascent, fast-growing segment of the country’s drug industry.
Hong Kong-based private equity firm PAG is paying $540m for a 58% stake in Hisun BioRay, the newly established biotech and biosimilars arm of major Chinese state-run generic company Zhejiang Hisun Pharmaceutical Co. Ltd. Asia-focused investment group PAG, which has $30bn in assets under management, has already made two recent investments in China’s biotech sector.
Hisun Pharma said it had been in talks with more than 40 potential investors over the sale of a controlling...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
